[Endocrine and cytostatic therapies in patients with breast cancer].
Kahlert
Steffen
S
Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe Grosshadern Klinikum der Universität München. steffen.kahlert@med.uni-muenchen.de
Sorokina
Y
Y
Bauerfeind
I
I
Friese
K
K
D000328:Adult; D000367:Age Factors; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D047072:Aromatase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000401:mortality; D018450:Disease Progression; D005260:Female; D006801:Humans; D008327:Mammography; D015201:Meta-Analysis as Topic; D008875:Middle Aged; D009362:Neoplasm Metastasis; D010166:Palliative Care; D017698:Postmenopause; D016032:Randomized Controlled Trials as Topic; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors